ENDO: THE PAIN AND THE GAIN

A A

What's not to like about this pharmaceutical outfit's brimming pipeline, locked-in market, and what S&P sees as its undervalued stock? As the population ages, we expect an increase in demand for pain-management therapies for both chronic conditions and surgical procedures. Standard &Poor's Equity Research thinks Endo Pharmaceuticals Holdings (ENDP ; recent price, $26.53), a leading provider of pain-management drugs, will benefit from the growth we see in this market, and we forecast midteens revenue and earnings growth over the next several years.

Business Week (http://yahoo.businessweek.com/investor/content/nov2005/pi2005111_5332_pi008.htm)